Glenmark Pharmaceuticals Ltd had received an approval from India’s drugs regulator to make and sell oral antiviral drug favipiravir for treating mild-to-moderate Covid-19 patients in the country
Glenmark gets approval for favipiravir: It is the first company in the country to receive such approval from the Controller General of India (DCGI). The company said in a statement that it has prepared the raw material (API) internally for this drug. He has also developed its compound (formulation).
Favipiravir is an anti-viral drug. This drug has shown the correct response against influenza virus. The use of this medicine for the treatment of influenza virus is permitted in Japan.